19.66
0.17 (0.87%)
| Previous Close | 19.49 |
| Open | 19.42 |
| Volume | 520,164 |
| Avg. Volume (3M) | 313,911 |
| Market Cap | 797,585,408 |
| Price / Book | 3.02 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -3.76 |
| Total Debt/Equity (MRQ) | 0.07% |
| Current Ratio (MRQ) | 14.34 |
| Operating Cash Flow (TTM) | -119.59 M |
| Levered Free Cash Flow (TTM) | -54.54 M |
| Return on Assets (TTM) | -23.10% |
| Return on Equity (TTM) | -49.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ArriVent BioPharma, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.75 |
|
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team’s deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 9.74% |
| % Held by Institutions | 85.20% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Hidden Lake Asset Management Lp | 30 Jun 2025 | 606,851 |
| 52 Weeks Range | ||
| Median | 31.00 (57.68%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 11 Nov 2025 | 31.00 (57.68%) | Buy | 19.36 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Nov 2025 | Announcement | ArriVent BioPharma Reports Third Quarter 2025 Financial Results |
| 22 Sep 2025 | Announcement | ArriVent Appoints Brent S. Rice as Chief Commercial Officer |
| 09 Sep 2025 | Announcement | Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |